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Primary bone lymphoma (PBL) is a rare disease for which specific therapeutic guidelines have not yet been established.
Due to common appearance in the elderly and recurring relapses, new treatments are required. We report the case of
multiple relapsed aggressive PBL effectively treated using Bendamustine and Rituximab. A 78-year-old male patient
presented with a painful mass in the left arm. Computed tomography (CT) showed a pathological tissue in the
humerus diaphysis infiltrating the muscle, confirmed by positron emission tomography (PET) scan. Indeed, PET
excluded pathological local lymph node involvement. Biopsy of the humerus revealed the presence of diffuse large
B cell lymphoma. Recommended treatments for PBL were used, but relapses after an initial complete response occurred.
Following the positive experience of Vacirca et al. the patient underwent Bendamustin 90 mg/mq gg1-2 q28 plus
Rituximab 375 mg/mq q28 (BR). Herein we report the first experience of BR combination in PBL and it proved to be an
efficacious and safe salvage therapy in relapsed/refractory PBL.
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Primary bone lymphoma (PBL) is a rare disease and ac-
counts for approximately 5% of extranodal lymphomas
(Mikhaeel 2012). Almost all lymphoma entities can ap-
pear as PBL (Zinzani et al. 2003), but up to 80% are dif-
fuse large B-cell lymphomas (DLBCL) (Mikhaeel 2012;
Jaffe 2009). Despite its relatively good short-term prog-
nosis, some patients eventually relapse (Ford et al. 2007).
Treatment options are very limited in this setting, espe-
cially for elderly patients who are not usually eligible for
standard salvage regimens followed by autologous stem
cell transplantation (ASCT). Bendamustine plus rituxi-
mab (BR) has proven to be effective and well tolerated in
relapsed/refractory DLBCL (Vacirca et al. 2014; Ohmachi
et al. 2013) and might therefore be an interesting alternative
for elderly patients suffering from relapsed/refractory PBL.
Herein, we present the first reported case of relapsed/
refractory PBL which was successfully treated with bend-
amustine in association with rituximab.* Correspondence: patriziamondello@hotmail.it
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A 78 year-old man with a left arm pain which had been
worsening for 4 months was admitted in March 2008 to
the orthopedic department. Physical examination revealed
the presence of a large humeral mass and concomitant
axillary lymphadenopathy. Computed tomography (CT)
showed a pathological tissue in the humerus diaphysis in-
filtrating the muscle and dubious involvement of locore-
gional lymph nodes (Figure 1, Panel A). Positron emission
tomography (PET) confirmed the presence of bone disease
while the locoregional lymph nodes were not fluorodeoxy-
glucose (FDG) avid, (Figure 1, Panel B) suggesting a react-
ive lymphadenopathy. Biopsy of the humerus revealed the
presence of a DLBCL. In immunohistochemistry, the neo-
plastic tissue was cluster of differentiation (CD) number
20 positive, CD79alfa +, CD 10+, CD3-, CD5-, CD23+,
BCL2-, BCL6+ with a Ki67 of 30%. According to the algo-
rithm by (Hans et al. 2004), it was sub-classified as germi-
nal center B-cell–like DLBCL. Successive bone marrow
trephine biopsy excluded the presence of bone marrow in-
volvement. In accordance with the WHO classification foris an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Computed tomography (CT) and Positron emission tomography (PET) images at the time of diagnosis. Panel A: CT scan
showing the pathological tissue of the mid-diaphysis of the left humerus infiltrating the adjacent biceps brachii muscle for a longitudinal extent
of 10.5 cm and axial dimensions of up to 5.5 cm. Several lymph nodes placed in the supraclavicular (1 cm), subclavian (2 cm) and in the axilla
(19 mm). Panel B: PET image at the diagnosis with FDG uptake restricted to the primary mass, sparing locoregional lymph nodes.
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fected by a primary bone lymphoma (Unni and Hogendoorn
2002). Because of muscle involvement per continuitatem a
stage IV EA bulky was assigned. Due to age and stage, the
International Prognostic Index (IPI) was 2. The patient was
in a good clinical condition (performance status of 0) and
echocardiography revealed a normal left cardiac function
(Lang et al. 2005) with an ejection fraction of 70%. There-
fore we administered in first line 6 cycles of rituximab,
cyclophosphomide, doxorubicin, vincristine and prednisone
(R-CHOP). Because CT scan showed only a partial remis-
sion (PR) and pain persisted, 90Y-ibritumomab tiuxetan
(90Y-IT) consolidation was administered on the basis of
the positive experience published by (Zinzani et al. 2008).
Also in our case the radioimmuneconiugate was able to
induce a PET-confirmed complete response (CR). One
year later he suffered a painful, local, histological-proven
relapse (Figure 2, Panel A). Due to the advanced age
(79 years), poor performance status at the time of relapse
and his ineligibility to ASCT, the patient underwent bi-
monthly administration of Rituximab for two years in order
to spare as much toxicity as possible. After 2 months the
patient’s general conditions improved and after 18 months
he achieved a second CR. Since at this time the disease was
confined to the bone without invasion of the surrounding
structures, bisphosphonates were administered concomi-
tantly. However, six months later, a second local relapse oc-
curred, which (as with the previous ones) was proved by
CT-PET (Figure 2, Panel B). Again no other tissues apart
from the bone were involved so the patient underwent
radiotherapy (RT) without any systemic treatment obtain-
ing a CR. Only four months later he presented a painful
mass in the left arm with bone and muscle involvement.
Ultrasonography showed a patchy and hypoechoic area of45x35 mm in the left biceps and X-ray revealed an osteo-
lytic area of the humerus diaphysis. The suspicion of re-
lapse was proven by biopsy and PET (Figure 2, Panel C) as
well as by bone marrow trephine biopsy which excluded
other disease localizations. Due to the lack of other
treatment options, he finally underwent Bendamustine
90 mg/m2 days 1–2 q28 plus Rituximab 375 mg/m2 every
28 days for 6 cycles. Because of the advanced age, pegfil-
grastim and antibiotic prophylaxis were administered to
prevent neutropenia and infectious complications. The
treatment was well tolerated. Reversible hematologic tox-
icity, mainly consisting of grade 2 neutropenia, occurred
after the fourth cycle. Non extra-hematologic toxicities
were registered with the exception of moderate fatigue.
After the first cycle local pain regressed, after the second
the mass was no longer palpable and after the fourth a
PET-CT was carried out (Figure 2, Panel D) which con-
firmed CR so the remaining two cycles were administered.
This result was quite unexpected since the patient had been
heavily pretreated and the third relapse occurred only four
months after RT. Moreover, the patient remained in CR for
12 months until he suffered the fourth relapse.
Discussion
Because of the rarity of this extranodal lymphoma en-
tity, no specific standard treatment has been established
up to now. In the 1990’s PBL first-line treatment con-
sisted of anthracycline containing therapy combined
with RT (Dubey et al. 1997; Baar et al. 1994), neverthe-
less more recent data suggests that the latter can be
omitted when administering at least 6 cycles of chemo-
therapy (Ramadan et al. 2007; Kim et al. 2012). The role
of consolidation RT in limited-stage PBL is not well de-
fined and remains a matter of debate. Indeed, in some
Figure 2 PET image after second (Panel A), third (Panel B) and fourth relapse (Panel C) as well as after BR treatment (Panel D).
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the addition of RT to an antracycline-based chemother-
apy has demonstrated to improve the outcome, while in
others it has not led to a reduction of relapses and sur-
vival rates when compared to patients who were treated
only with chemotherapy (Haddy et al. 1988; Ramadan
et al. 2007; Bruno Ventre et al. 2014). Moreover, only a
few years ago, a large randomized trial of the GELA
group showed that the addition of RT consolidation
after CHOP chemotherapy in patients with localized
stage DLBCL did not provide any advantage over CHOP
alone (Bonnet et al. 2007). One year later, a German study
confirmed in a historical comparison that the addition of
RT to chemotherapy in patients with bulky and extranodal
disease who achieved CR after R-CHOP14 did not im-
prove PFS (Pfreundschuh et al. 2008a). However, all these
studies were retrospective and the number of patients was
relatively small, which is why a prospective confirmatory
trial is needed. Since the addition of the monoclonal anti
CD20 antibody rituximab significantly improved the out-
come (Ramadan et al. 2007; Persky et al. 2008) and PFS of
patients with localized DLBCL without leading to a signifi-
cant increase of toxicity (Pfreundschuh et al. 2011, 2008b),
it was administered concomitantely to CHOP in the
present case as well.
Given that after induction treatment the patient achieved
only a PR, consolidation treatment was needed. Due to the
relatively low level of evidence for RT in this setting as
mentioned above and considering the positive results of thephase II trial by (Zinzani et al. 2008), 90Y-IT consolidation
was administered and the patient achieved a CR.
At the time of the first relapse, in order to positively in-
fluence the course of the disease, like in many other neo-
palsias (Coleman et al. 2012), bisphosphonates were added
to the immunotherapy. Although the antineoplastic mech-
anisms of bisphosphonates are not fully clarified yet, their
positive effect on disease control can be at least partially
explained by alteration of the bone microenvironment
(Power and Bird 2009; Guise 2008). Moreover, at this time
the patient was in poor clinical conditions and due to his
advanced age and inelegibility for a platinum containig sal-
vage chemotherapy as well as successive autologous stem
cell transplantation, we decided to administer bimonthly
Rituximab in order to provide an efficient treatment with-
out excessive toxicity (Coiffier et al. 1998; Rothe et al. 2004;
Tobinai et al. 2004). Unexpectedly the patient achieved a
second CR. Nevertheless, he relapsed again and since PBL
was still confined to the initial site of the disease, he suc-
cessfully underwent RT, in line with a previously published
experience (Dubey et al. 1997).
At the third relapse, due to the lack of other treatment
options and to the positive experience of (Vacirca et al.
2014), the patient underwent BR achieving a CR. At this
time, BR had demonstrated to be an active regimen for in-
dolent relapsed/refractory NHL (Rummel et al. 2005) and
for patients with relapsed/refractory DLBCL (Vacirca et al.
2014), leading to a ORR of nearly 46% with a median dur-
ation of response of 17.3 months with a favorable toxicity
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ment option for patients who are inelegible for a platinum
based chemotherapy and consolidation with autologous
stem cell transplantation.
In recent years, the efficacy of many novel molecules
has been evaluated in several international clinical trials,
but only few of them proved to be efficient. One of them
was Everolimus, a mTOR inhibitor, used as a single-agent
in elderly, heavily pretreated patients affected by aggressive
lymphomas (Witzig et al. 2011). Results were promising
and an ORR of 30% and time to relapse of nearly 6 months
were observed. Similar results were obtained using lenali-
domide, an immunomodulating agents, as single-agent in
73 relapsed/refractory DLBCL patients (Wiernik et al.
2008). In comparison with the results of these trials, BR
had the best long-term results with a almost double the
time to relapse and a more favourable toxicity profile.
To our knowledge, this is the first report regarding the
use of BR as salvage therapy in relapsed/refractory PBL.
Despite the aggressive clinical course, BR in fourth line
treatment was able to induce a CR and to maintain it for a
year – a comparable result to the more aggressive R-CHOP
administered in first line. Moreover, despite the advanced
age of the patient, no important hematologic and extrahe-
matologic toxicities occurred.
In conclusion, BR seems to be an effective salvage immu-
nochemotherapy regimen for refractory PBL not eligible for
a platin containing salvage chemotherapy and ASCT.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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